Season's Savings | ₹5/mo for 3 months
₹199/month after first 3 months. Renews automatically. Terms apply.
13: Peptalk Week in Review — November 6, 2026
Failed to add items
Add to cart failed.
Add to wishlist failed.
Remove from wishlist failed.
Follow podcast failed
Unfollow podcast failed
-
Narrated by:
-
Written by:
This week: the week's biggest story — Novo Nordisk beats expectations and raises its full-year guidance, with the once-daily Wegovy pill doing DKK 5.39 billion in the quarter, about 17% ahead of forecasts, while injectable Wegovy and Ozempic both slip.
Plus: new preliminary research from the American Heart Association finds GLP-1 drugs outperformed Metformin for people with Prediabetes and obesity — 1.5x more likely to return to normal blood sugar, 31% lower risk of developing type 2 diabetes — with the observational caveats kept in frame;
Employers keep pulling GLP-1 coverage for weight loss (53%, down from 57%, the first decline in three years) while Novo partners with Andel so companies can subsidize Wegovy outside insurance at $149 a month for the pill and $199 for the injection; and quick hits on Ascletis's ObesityWeek posters and the HHS peptide-compounding comment deadline.
For research and informational purposes only — not medical advice. Nothing on this show is a recommendation for any product or treatment.
Sources:
• Novo Nordisk, Company announcement No 65 / 2026 — Financial report for the period 1 January 2026 to 30 September 2026 (Nov 4, 2026), via GlobeNewswire syndication: Q3 sales DKK 79,195m (+4% CER), adjusted operating profit DKK 31,720m (+27% CER), Wegovy pill DKK 5,394m, guidance raised to −2% to +2% at CER.
• TradingView / dpa-AFX (Nov 4, 2026) — Novo Nordisk Q3 adj. operating profit increases, obesity sales up 22%, raises 2026 outlook: https://www.tradingview.com/news/dpa_afx:73790cd8c7838:0-novo-nordisk-q3-adj-operating-profit-increases-obesity-sales-up-22-raises-2026-outlook/
• Sweden Herald (Nov 4, 2026) — Novo Nordisk beats third-quarter expectations as sales top forecasts: https://swedenherald.com/article/novo-nordisk-beats-third-quarter-expectations-as-sales-top-forecasts
• American Heart Association news release (Nov 2, 2026) — GLP-1 meds linked to lower diabetes, heart risks than standard diabetes prevention med (256,492 adults with Prediabetes and obesity; preliminary abstract presented at Scientific Sessions 2026): https://newsroom.heart.org/news/glp-1-meds-linked-to-lower-diabetes-heart-risks-than-standard-diabetes-prevention-med
• The Inference (Nov 2, 2026) — Employers are cutting GLP-1 coverage; Novo Nordisk sells Wegovy outside insurance for $149 to $199 a month (WTW survey, Marsh 2026 survey, Andel partnership Oct 28, 2026): https://theinference.org/article/employers-are-cutting-glp-1-coverage-novo-nordisk-sells-wegovy-outside-insurance-for-149-to-199-a-month
• Journalarta (Nov 4, 2026) — First GLP-1 weight-loss pill approved in Australia (Therapeutic Goods Administration): https://journalarta.com/en/2026/11/04/first-glp-1-weight-loss-pill-australia/
• Ascletis Pharma / PR Newswire via Morningstar (Nov 2, 2026) — Ascletis to present study results of oral small-molecule GIPR agonist ASC48 and GLP-1R/GIPR/GCGR triple peptide agonist ASC37 at ObesityWeek 2026: https://www.morningstar.com/news/pr-newswire/20261102cn85414/ascletis-to-present-study-results-of-oral-small-molecule-gipr-agonist-asc48-and-glp-1rgiprgcgr-triple-peptide-agonist-asc37-at-obesityweek-2026
• Federal Register, Doc. 2026-22192 (Docket HHS-OASH-2026-0496) — HHS enforcement discretion policy for 503A compounding of six peptides; public comment open until November 13, 2026: https://www.federalregister.gov/public-inspection/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
A Spoke-Media production:
https://www.spoke-media.com